Palvella Therapeutics, Inc.
PVLA
$156.13
-$0.42-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.93M | 5.52M | 4.18M | 3.65M | 4.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.41M | 14.86M | 11.30M | 10.18M | 9.25M |
| Operating Income | -21.41M | -14.86M | -11.30M | -10.18M | -9.25M |
| Income Before Tax | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.87M | -15.77M | -12.71M | -11.35M | -9.47M |
| EBIT | -21.41M | -14.86M | -11.30M | -10.18M | -9.25M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.52 | -1.20 | -1.07 | -1.03 | -0.86 |
| Normalized Basic EPS | -0.95 | -0.75 | -0.67 | -0.64 | -0.54 |
| EPS Diluted | -1.52 | -1.20 | -1.07 | -1.03 | -0.86 |
| Normalized Diluted EPS | -0.95 | -0.75 | -0.67 | -0.64 | -0.54 |
| Average Basic Shares Outstanding | 14.36M | 13.09M | 11.87M | 11.06M | 11.05M |
| Average Diluted Shares Outstanding | 14.36M | 13.09M | 11.87M | 11.06M | 11.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |